Introduction
============

Safflower (*Cathamus tinctorius* L.) seeds are a good source of edible oil rich in α-linoleic acid (n-6), which has a hypocholesterolemic effect. Safflower seeds have long been used clinically in Korea to promote bone formation and to prevent osteoporosis \[[@B1]\]. Several reports suggest that safflower seed powder or extract promotes recovery from bone fractures and stimulates differentiation of osteoblasts in rats \[[@B2]-[@B5]\]. Our previous studies showed that mixed polyphenol compounds extracted from defatted safflower seeds stimulates proliferation of ROS 17/2.8 osteoblast-like cells \[[@B6],[@B7]\]. Furthermore, feeding the seed powder \[[@B6]\] and its defatted ethanol extract \[[@B7]\] markedly attenuates bone loss in ovariectomized rats. Kang et al. \[[@B8]\] and Kim et al. \[[@B9]\] isolated and identified phenolic compounds from roasted safflower seeds, and found that safflower seeds were a rich source of not only phytoestrogen-like flavones (acacetin and acacetin 7-*O*-glucoside) and lignans (matairesinol and 8-hydroxyarctigenin), but also serotonin derivatives (N-feruloylserotonin and N-(p-coumaroyl) serotonin) that exhibit antioxidant activity *in vitro* \[[@B8],[@B9]\]. More recently, we showed that a water extract of germinated safflower seeds has proliferative and differentiation effects on mouse calvarial bone cells, and a major component for the effects was trachelogenin \[[@B10]\].

Therefore, seed components with bone-forming effects can be utilized as health foods to prevent osteoporosis in postmenopausal women. Safflower seed tablets have been formulated as a health food by simply grinding and pressing seed powder, but consumers complained due to the rancidity of the tablet contents during storage. To make up for the shortcomings of such tablets, tea-bag \[[@B11]\] and drink-type products \[[@B11]-[@B13]\] have been prepared using safflower seed powder and ethanol extracts. These products have been tested for antioxidant activity \[[@B12]\], sensory qualities, and product quality characteristics \[[@B11]-[@B13]\] but not for their physiological effects in animals and humans. We prepared a granule-type tea, including an ethanol extract of defatted safflower seeds, and reported the hypolipidemic and of the safflower and placebo teas antioxidant effects of the tea in ovariectomized rats \[[@B14]\]. In the present study, we supplemented with the same safflower granular tea to determine the effects on bone metabolism and antioxidant status markers in postmenopausal women.

Subjects and Methods
====================

Subjects
--------

Subjects living in the Daegu-Gyeongbuk area were selected, including 50 post-menopausal women with ages between 49 and 64-years who had not been treated with hormone replacement therapy or any other medication affecting hormone status. Age, lifestyle factors, and gynecological and obstetric history of the subjects were investigated through a general survey questionnaire. This study was approved by the ethics committee of the Catholic University of Daegu, and informed consent was obtained from each subject. The 50 subjects were randomly assigned to a safflower tea (Saf-tea) group of 34 subjects and a placebo group of 16 subjects. Of the 50 subjects, seven from the Saf-tea group and three from the placebo group withdrew from the study during the 6-month supplementation period, so a total of 40 subjects completed the study. The number of subjects in the placebo group was rather small compared with that of the test group, because it was difficult to recruit more subjects for the placebo group due to ethical reasons.

Safflower tea preparation
-------------------------

Five hundred grams of safflower seeds (safflower seeds: *Carthamus tinctorious* L.) harvested from a farm in Uisong, Geyongbuk, Korea were washed, roasted at 200℃ for 5 min, ground, and extracted twice with hexane to remove lipids under reflux. The defatted seeds were further extracted with 80% ethanol, and the extract was used to prepare the granular safflower tea. The safflower tea contained 13% extract (w/w), ssangwha tea extract, soy isoflavones, glucose, mannitol, maltodextrin, lactose, and sodium silicoalumenate ([Table 1](#T1){ref-type="table"}). The ssangwha tea extract was added to help blood circulation as well as reduce the bitter taste of the safflower seed extract. A small amount of soy isoflavones was added to enhance the isoflavone effect in the tea but it was not expected to have any effect alone. Glucose was added for palatability, and the remaining ingredients were needed to formulate the tea granules. Ten grams of tea granules were packaged in each pack, and two packs were taken daily by the subjects in the morning and evening, respectively. Safflower polyphenol content was estimated to be 72 mg including 18 mg of serotonin derivatives, which was comparable to the amount recommended for daily intake of safflower tablets that had been for sale. The placebo tea was prepared the same as the safflower tea except that the safflower extract and soy isoflavones were replaced with maltodextrin.

Study design
------------

The subjects who consented to participate were individually interviewed to obtain information on their general and health-related characteristics, including diet and anthropometric indices. The subjects were also advised not to change their usual diet and health-related habits during the test period. One week later, fasting blood samples were taken, and bone density was measured for baseline data. Each subject was then given enough Saf-tea or placebo to last 1 month in a double-blind fashion. They were instructed to take two packs in warm water per day, *i.e.*, one packet each in the morning and the evening. The same procedure was repeated until completion of the 6-month study. Compliance for taking the Saf-tea or placebo was encouraged by phone calls in addition to counseling as needed for any complications that the subjects encountered. During the 6-month test period, blood samples were taken at months 3 and 6, and life style factors, anthropometric indices, dietary nutrient intakes, and bone density were examined at month 6 by the same procedure as used for baseline measurements.

Lifestyle and dietary measurements
----------------------------------

The questionnaire included questions about demographic characteristics and lifestyle and maternal factors. The selected lifestyle and maternal factors were cigarette smoking, alcohol intake and physical exercise, type of menopause, and experience with contraceptive pills or hormone replacement. Dietary intake data were collected by a trained dietitian using the 24-hr recall method at months 0 and 6 and were analyzed for energy and nutrient contents using the computer aided nutritional analysis, version 3.0 program developed by The Korean Nutrition Society (2005). Phytoestrogen intake from the diet was estimated by food frequency, as described in a previous study \[[@B15]\] and that from safflower tea was estimated by the safflower seed polyphenol contents reported by Kang et al. \[[@B8]\].

Blood analysis
--------------

Serum genistein was quantified using time-resolved fluoroimmunoassay with a Labmaster (Turku, Finland) Genestein kit (1212-2003), and enterolactone was quantified in the same manner with a Labmaster Enterolactone kit (1212-2001). Serum contents of α-tocopherol and retinol were determined by high performance liquid chromatography \[[@B16]\] with slight modifications, after serum samples were extracted with hexane. A C-18 µBondapak (300 × 8 mm) stainless steel column (Waters, Milford, MA, USA) was used, and the analysis was performed isocratically with methanol/H~2~O (97:3,v/v) as the mobile phase and ultraviolet detection at 292 nm. Serum thiobarbituric acid reactive substances (TBARS) were measured by the methods of Yagi \[[@B17]\] using 1,1,3,3,-tetraethoxypropane as the standard. Serum osteocalcin was measured by the IRMA method with a Osteocalcin-IRMA kit from Biosourse™ (Invitrogen, Carlsbad, CA, USA). Fasting blood samples were analyzed for serum alanine amintransferase (ALT), aspartate amintransferase (AST), blood urea nitrogen (BUN), and creatinine with an automated analyzer (Cobas Integra 700, Roche, Switzerland).

Bone density measurements
-------------------------

Bone mineral density (BMD) of the lumbar spine (L1-L4) was measured using dual energy X-ray absorptiometry (Hologic QDR-4500, Waltham, MA, U.S.A) at baseline and after 6 months of tea supplementation. Regions of interest for the lumbar spine were defined according to the manufacturer\'s guidelines. All measurements were made and analyzed by experienced operators at Catholic University\'s Daegu Hospital. The *in vivo* precision error for BMD was 1%.

Statistical analysis
--------------------

A chi-square-test was used to investigate if there were any differences in general characteristics and lifestyle factors between the test and placebo groups at baseline. Paired *t*-tests were used to compare the blood analysis, anthropometric and dietary measurement, and BMD data in the test and placebo groups before and after supplementation. An analysis of covariance (ANCOVA) was used to evaluate differences in values before and after supplementation between the test and placebo groups. All analyses were performed using the SPSS package (SPSS, Inc., Chicago, IL, USA).

Results
=======

General subject characteristics
-------------------------------

The ages of the subjects ranged from 49 to 64 years, with a mean ± standard deviation of 54.0 ± 1.9 years for the placebo group and 55.6 ± 3.6 years for the Saf-tea group. Both groups had similar heights, weights, body mass indices (BMI), and waist-hip ratios (WHR), which did not change in the placebo or Saf-tea groups during the 6-month supplementation period, except for a slight increase in WHR in the Saf-tea group ([Table 2](#T2){ref-type="table"}). The maternal and menopausal characteristics of the subjects were not different between the placebo and Saf-tea groups, and menopause was confirmed in both groups by estradiol levels lower than 30-400 pg/mL. Drinking, smoking, and exercise habits were similar between the placebo and the Saf-tea groups and did not change during the 6-month supplementation period.

Nutrient intake of the subjects
-------------------------------

[Table 3](#T3){ref-type="table"} presents the dietary intake of nutrients, calcium, and vitamins A, C, and E in the placebo and Saf-tea groups before and after 6 months of supplementation. The Saf-tea group appeared to have a slightly higher energy intake than the placebo group at baseline and this seemed to be due to a somewhat higher intake of carbohydrate. But throughout the study period, no significant changes in either the placebo or Saf-tea group were observed before and after supplementation, except for vitamin A intake, which was higher at 6 months than at baseline in the Saf-tea group. After 6 months, changes in nutrient intake, including other nutrients not shown in [Table 3](#T3){ref-type="table"}, did not differ between the placebo and Saf-tea groups.

Phytoestrogen intake and body status
------------------------------------

Daily phytoestrogen intake by the subjects was estimated from the diet at baseline and from the safflower tea ([Table 4](#T4){ref-type="table"}). The dietary phytoestrogens included isoflavones (daidzein, genistein, formononectin, and biochanin A), coumesterol, and ligans (matairesinol, secoisolarciresinol, enterolactone, and enteroldiol). Daidzein and genistein comprised the majority of dietary phytoestrogen isoflavones at 70-75%, whereas coumestetol and lignan were found at 22-28% and 2-4%, respectively. The intake of total dietary phytoestrogens appeared higher, although not significantly, in the Saf-tea group that was supplemented with an additional 54.2 mg of phytoestrogen plus 18 mg of serotonin derivatives from the tea. This resulted in a more than two-fold higher intake of phytoestrogen and serotonin derivatives in the Saf-tea group than the placebo group.

Several kinds of phytoestrogens were ingested by the subjects, but only serum levels of genestein and enterolactone, which are major metabolites of isoflavones and lignans, were measured in this study. The concentrations of serum genistein in the placebo and Saf-tea groups were 192 ± 153 and 178 ± 126 nmol/L, respectively, at baseline, which were not significantly different ([Table 5](#T5){ref-type="table"}). However, serum genistein levels increased significantly in the Saf-tea group following 6 months of tea supplementation compared to baseline values, and differences in the genestein levels of the placebo group before and after supplementation were observed. The same result was found for changes in serum enterolactone levels. The enterolactone level at baseline (37 ± 24 nmol/L) in the Saf-tea group almost doubled to 68 ± 42 nmol/L after Saf-tea supplementation, whereas it decreased slightly in the placebo group.

Bone marker levels and BMD
--------------------------

[Table 6](#T6){ref-type="table"} shows serum osteocalcin levels, urinary deoxypyridinoline (DPD) excretion, and lumbar-spine BMD at several bone locations in the placebo and Saf-tea study groups before and after 6 months of tea supplementation. Serum osteocalcin did not change in the placebo group but decreased in the Saf-tea group after 6 months; however, the Saf-tea group did not show greater decreases than the placebo group for the differences between the baseline and 6-month values (*P* = 0.076 by ANCOVA). Urinary DPD excretion was not changed by Saf-tea supplementation. BMD (L1-L4) decreased in the placebo group but not in the Saf-tea group after 6 months of supplementation, although the differences between the baseline and 6-month values of the two groups did not show safflower tea effects.

Antioxidant vitamin and TBARS levels
------------------------------------

[Fig. 1](#F1){ref-type="fig"} shows the serum levels of retinol, α-tocopherol, and ascorbic acid for the study subjects before and during 6 months of supplementation with the placebo and Saf-tea. Levels of each vitamin were not different in the placebo and Saf-tea groups at baseline. Retinol levels did not change after 3 months but increased both in the placebo (*P* = 0.011) and Saf-tea tea (*P* = 0.000) groups after 6 months (both 0.46 ± 0.10 µg/ml) compared to baseline values (0.53 ± 0.09 and 0.58 ± 0.14 µg/ml, respectively), and no difference (*P* = 0.168 by ANCOVA) in retinol level were observed between the placebo and Saf-tea groups after 6 months of supplementation ([Fig. 1A](#F1){ref-type="fig"}). α-Tocopherol appeared to decrease in the placebo group after 3 months but returned to baseline after 6 months ([Fig. 1B](#F1){ref-type="fig"}). However, α-tocopherol increased significantly in the Saf-tea group (*P* = 0.000) after 6 months (12.75 ± 4.36 µg/ml), compared to the value (9.00 ± 2.26 µg/ml) at baseline and at 3 months. Differences between baseline and 6-month α-tocopherol values were significantly higher in the Saf-tea group than in the placebo group (*P* = 0.029 by ANCOVA). Vitamin C levels appeared to be the same in the placebo group but increased significantly in the Saf-tea group during the 6 months (1.10 ± 0.45 µg/ml) compared to baseline levels (0.92 ± 0.44 µg/ml, *P* = 0.036). Nevertheless, no difference (*P* = 0.175 by ANCOVA) in ascorbic acid levels was observed in the placebo and Saf-tea groups after 6 months of supplementation ([Fig. 1C](#F1){ref-type="fig"}). [Fig. 2](#F2){ref-type="fig"} shows serum TBARS levels in the study groups during tea supplementation. TBARS levels did not change in the placebo group but appeared to continue to decrease in the Saf-tea group during the 6 months, resulting in a significant decrease after 6 months (1.34 ± 0.32 MDA nmol/ml) compared to baseline (1.50 ± 0.3 MDA nmol/ml, *P* = 0.002). The difference between the baseline and 6-month TBARS values was significantly lower in the Saf-tea group than the placebo group (*P* = 0.045 by ANCOVA).

[Table 7](#T7){ref-type="table"} shows serum levels of AST, ALT, BUN, and creatinine in the study subjects before and during 6 months of supplementation in the placebo and Saf-tea groups. No differences were observed between the groups, time periods, or changes in the placebo and Saf-tea groups after 6 months of supplementation.

Discussion
==========

We evaluated the effectiveness and safety of safflower tea administered to postmenopausal women to attenuate osteoporosis and improve body antioxidant status. Drinking the safflower tea provided 72 mg of safflower polyphenols including isoflavones, lignans, and serotonin derivatives increased serum content of isoflavones and enterolactone, a major metabolite of lignans, and probably serotonin, although the latter was not measured. Supplementing with flaxseed, a rich source of enterolignan precursors (secoisolariciresinol and matairecinol) increases serum enterolactone concentrations \[[@B18]\] and the processing of flaxseed such as milling and crushing enhances enterolignan bioavailability \[[@B19]\] in humans. The intake of matairesinol, a major lignan in safflower tea, by the present study subjects was estimated to be approximately 10 mg per day, which was lower than that by flaxseed supplementation \[[@B18],[@B19]\]. Matairesinol in the safflower tea was from a solvent extract, which appeared to be more easily available to the body than enterolignans from flaxseed powder. It is also noteworthy that the much smaller intake (\~18 mg) of soy isoflavones included in safflower tea increased serum genestein levels compared to 70-200 mg soy isoflavone/day used in most supplementation studies \[[@B20]-[@B22]\]. This effect may be attributable to the serotonin derivatives (18 mg/day), one of the major polyphenolic components in the tea. However, the increases in body levels of isoflavones and enterolactone did not coincide with any improvements in the bone metabolic markers, although BMD appeared to remain the same in the safflower tea group compared to a decrease in the placebo group after 6 months of supplementation. The estrogenic bone protection activities of isoflavones and lignans have been repeatedly suggested and shown in a few animal and cell studies using isoflavones from soy and flaxseed but have rarely been confirmed in supplementation studies using humans. The main reason may be the amount of isoflavones or lignans used in the studies. When ovariectomized rats are fed defatted safflower powder \[[@B6]\] or ethanol extract \[[@B7]\], 4-4.4 mg of safflower polyphenols per 250 g of rat were observed, which is the equivalent of 800-880 mg per 50 kg body weight, whereas only 72 mg of safflower polyphenols were supplied to the present subjects who weighed 54-55 kg. Supplementing with isoflavones from soy and red-clover reduces bone loss after a 1 year intake of 43.5 mg/day \[[@B23]\] and increases BMD following six months of intake of 57-90 mg/day in postmenopausal women \[[@B24]-[@B26]\]. However, supplementing with 118 mg/day of isoflavones for 3 months does not have an effect on bone resorption markers \[[@B21]\], and 90 mg/day for 8 weeks or 96 mg/day for 9 months \[[@B27]\] does not improve BMD compared to placebo. Wu et al. \[[@B21]\] indicated that intervening with isoflavones (75 mg/day for 1 year) in postmenopausal Japanese women has a modest effect on BMD compared to the effects found in Westerners, and the effect was shown only at Ward\'s triangle. Lee et al. \[[@B28]\] reported that supplementation with three levels of isoflavones (100, 150, 200 mg/day) for 6 months appeared to reduce both serum osteocalcin and urinary excretion of DPD in postmenopausal women. Uesugi et al. \[[@B29]\] reported that 62.8 mg/day of isoflavones for 4 weeks reduced urinary DPD significantly and serum osteocalcin non-significantly in perimenopausal women. The effects of flaxseed lignans on bone health have been shown by a much a smaller number of human studies compared to those of soy isoflavones. Randomized control studies with either postmenopausal women \[[@B30]-[@B32]\] or adult men \[[@B32]\] did not show any effects on BMD and biomarkers following flaxseed supplementation. In contrast, Ward et al. \[[@B33]\] warned that feeding flaxseed secoisolariciresinol through a mother\'s milk may reduce bone strength in young rats. However, these results do not exclude the possibility of bone promoting effects of flaxseed. More discriminating research protocols are necessary to demonstrate the effects of components from flaxseed or other plants in different age groups and physiological states. The present study was the first human study on bone using tea containing safflower polyphenols in postmenopausal women with a matching placebo group. Although we were unable to attain definite positive bone health results, we found that the amount of tea used for the 6-month period of the present study was acceptable, judging from interviews with subjects. The safflower tea used in the present study had a considerable amount of serotonin derivatives (\~18 mg), which is not found in soybeans, flaxseed, or Ssangwha extract. Serotonin aids bone formation in growing rats \[[@B34]\], and serotonin-abundant safflower seed powder has the same effect in rats with bone-fractures \[[@B2]-[@B5]\], as well as reducing bone loss in ovariectomized rats \[[@B6]\]. Therefore, it is worth attempting to use safflower seed products containing higher amounts of serotonin and phytoestrogens in human trials employing a crossover design to reduce inter-individual variations that seem to obscure statistical significance.

The safflower tea reduced peroxidation status in the body as shown by the reduction in serum TBARS levels. This was accompanied by an increase in body antioxidant capacity, as seen with higher levels of vitamins E, A, and C. Increases in serum vitamin concentrations were not related to changes in dietary intake of the Saf-tea and placebo groups after 6 months of supplementation. Therefore, the effects are regarded as being mainly from safflower tea polyphenols composed of flavones, lignin, and serotonin derivatives, which have radical scavenging activity and inhibit lipid peroxidation in *in vitro* \[[@B8],[@B9]\] and *in vivo* \[[@B14]\] studies. Isoflavones have antioxidant activity \[[@B35]\]. Choi et al. \[[@B36]\] reported that supplementing with 200 mg of isoflavones/day for 12 weeks increases total antioxidant status both in peri- and post-menopausal women. Furthermore, Lee et al. \[[@B37]\] reported that 80 mg isoflavones/day decreases plasma malondialdehyde and increases total antioxidant status in hypercholesterolemic but not in normolipidemic postmenopausal women. However, they did not measure body antioxidant compounds individually. The flaxseed lignan secoisolariciresinol and its metabolites enterolactone and enterodiol exert antioxidant activity within *in vitro* systems \[[@B38],[@B39]\]. Prasad \[[@B38]\] showed decreases in aortic malondialdehyde concentrations in rabbits fed a high cholesterol diet. In humans, dietary intake of 50 g of flaxseed for 4 weeks does not affect plasma hydroperoxide levels \[[@B40]\], whereas low serum enterodiol concentrations are associated with increased lipid oxidation \[[@B41]\]. The following studies with postmenopausal women failed to show antioxidant activity in humans supplemented with flaxseed for 4 weeks \[[@B42]\], or by a 6-week supplementation with 500 mg of secoisolariciresinol isolated from flaxseed \[[@B43]\]. In contrast, we found definite antioxidant effects with safflower tea containing 72 mg of safflower polyphenols, less than the amount used in the soy isoflavone and flaxseed lignan studies.

Our results showed that the safflower tea had strong antioxidant activity that helped reduce the incidence of degenerative disease in old age and has the potential to maintain bone health in postmenopausal women.
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![**Changes in serum cocnentrations of retinol, α-tocopherol and ascorbic acid of the subjects after three and six months of safflower tea supplementation.** ^\*^,^\*\*^Significantly different from baseline by paired t-test at *P* \< 0.05 and *P* \< 0.001. ^\*\*\*^Significantly different from baseline by paired t-test at *P* \< 0.001 and from placebo group by ANCOVA at *P* \< 0.05.](nrp-5-20-g001){#F1}

![**Changes in serum cocnentrations of TBARS of the subjects after three and six months of safflower tea supplementation.** ^\*\*^Significantly different from baseline by paired t-test and from placebo group by ANCOVA at *P* \< 0.05.](nrp-5-20-g002){#F2}
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Compositions of the safflower and placebo teas
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^1)^ *Rubus coreanus-Atractylodes japonica*

^2)^ 30% soy isoflavone

###### 

Marternal and menopausal characteristics and anthropomeric indices of the study subjects
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^1)^ All values are means ± SD.

^\*^Significantly different from baseline by paired t-test at *P* \< 0.05
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Changes in daily energy, Ca and vitamins A, C, E intakes of the study subjects after six months of safflower tea supplementation
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^1)^ All values are means ± SD.

^2)^ By ANCOVA of changes from baseline between placebo and Saf-tea groups

^\*^Significantly different from baseline by paired t-test at *P* \< 0.05
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Intakes of total phytoestrogen and serotonin derivatives of the subjects

![](nrp-5-20-i004)

^1)^ All values are means ± SD.

^2)^ Of 29 mg, 18 mg was supplied from soy isoflavone included in safflower tea.
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Changes in serum genistein and enterolactone levels of the subjects after six months of safflower tea supplementation
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^1)^ All values are means ± SD.

^2)^ By paired t-test between baselin and 6 mon

^3)^ By ANCOVA of changes from baseline between placebo and Saf-tea groups
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Changes in indices of bone status of the subjects after six months of safflower tea supplementation
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^1)^ All values are means ± SD.

^2)^ By paired t-test between baseline and 6 mon

^3)^ By ANCOVA of changes from baseline between placebo and Saf-tea groups
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The changes in concentrations of serum BUN, creatinine, AST and ALT of study subjects after six months of safflower tea supplementation
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^1)^ All values are means ± SD.
